Praxis Precision Medicines
PRAX
100 hedge funds and large institutions have $863M invested in Praxis Precision Medicines in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 16 reducing their positions, and 7 closing their positions.
181% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 16
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
9% more capital invested
Capital invested by funds: $792M → $863M (+$71.3M)
9% more funds holding
Funds holding: 92 → 100 (+8)
0.13% more ownership
Funds ownership: 6.38% → 6.51% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$14.9M |
| 2 |
BlackRock
New York
|
+$6.88M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.05M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$4.47M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$8.73M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.31M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$4.62M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$3.91M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$3.62M |
PRAX Hedge Fund Activity: Q4 2021 in Review
100 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q4 2021, worth a combined $863M — up 9% from $792M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PRAX positions and 7 closed out — a net gain of 9 holders — while 45 added to existing stakes and 16 trimmed.
The largest buyer was State Street, adding an estimated $14.9M. The largest seller was Blackstone Inc, cutting an estimated $8.73M.
- 100 institutional investors held Praxis Precision Medicines (PRAX) as of Q4 2021, up from 92 in Q3 2021.
- Funds reported $863M of Praxis Precision Medicines stock for Q4 2021, up 9% quarter-over-quarter.
- 16 funds opened new Praxis Precision Medicines positions in Q4 2021 and 7 closed out, a net change of +9 holders.
- The largest Praxis Precision Medicines buyer in Q4 2021 was State Street, an estimated $14.9M added.
- The largest Praxis Precision Medicines seller in Q4 2021 was Blackstone Inc, an estimated $8.73M sold.
Based on aggregated 13F filings for Q4 2021.